GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
Thursday, GSK plc (NYSE:GSK) announced headline results of a phase 2 trial for its mRNA seasonal influenza vaccine program.
週四，GSK公司（紐交所：GSK）宣佈其mRNA季節性流感疫苗計劃的2期試驗的頭條成果。
The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care.
該試驗研究了一系列mRNA製劑在老年人和年輕人中的應用，以評估與當前標準治療相比，能夠改善對甲型和乙型流感病毒的免疫反應的疫苗候選物。
The data demonstrated positive immune responses against influenza A and B strains compared to the current standard of care, meeting all predefined success criteria in the tested age groups of older and younger adults.
數據顯示，在老年人和年輕人這兩個年齡組中，與當前的標準治療相比，對甲型和乙型流感病毒的免疫反應均呈現積極的結果，並滿足了所有預先設定的成功標準。
Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech.
此外閱讀：GSK停止研發單純皰疹病毒疫苗，爲Moderna、BioNTech等其他競爭者鋪平道路。
Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested.
中期數據表明，對於所有測試的mRNA製劑來說，疫苗候選物具有可接受的安全性和反應原性。
These results build on the previous phase 2 trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile.
這些結果是對之前第2期試驗的進一步補充，證實了mRNA平台能夠引發強效的全面抗體效價，並具有可接受的安全性。
With these results, the GSK mRNA seasonal influenza vaccine program will progress into late-stage clinical development.
根據這些結果，GSK的mRNA季節性流感疫苗計劃將進入後期臨床發展階段。
Vaccine candidate based on CureVac N.V.'s (NASDAQ:CVAC) proprietary second-generation mRNA backbone
基於CureVac N.V.（納斯達克：CVAC）的專有第二代mRNA骨架的疫苗候選物。
The Phase 2 study was initiated following interim data reported in April from the Phase 2 part of the ongoing combined Phase 1/2 study in seasonal influenza.
隨着4月份報告的臨時數據，第2階段研究開始進行，該研究是在季節性流感的進行中的第1/2階段研究的一部分。
In July, GSK and CureVac restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investment and focus on their respective mRNA development activities.
7月份，GSK和CureVac將現有的合作關係重組爲新的許可協議，允許公司優先投資並專注於各自的mRNA開發活動。
Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases.
自2020年以來，格拉克斯史密斯和CureVac一直在共同開發用於傳染病的mRNA疫苗。
Price Action: GSK stock is down 0.91% at $43.37, and CVAC stock is down 1.98% at $2.97 at last check Thursday.
價格走勢：GSK股票下跌0.91%，報43.37美元；CVAC股票下跌1.98%，報2.97美元，截至週四最後交易。
- Nvidia AI Chips Headed to Saudi Arabia, US Reassesses Export Ban
- 英偉達人工智能芯片將被出口到沙特阿拉伯，美國重新評估出口禁令
